Birth Control Pills with Higher Estrogen Content
Combined oral contraceptives containing 30-35 µg of ethinyl estradiol are considered "higher dose" formulations and include pills such as those containing ethinyl estradiol 30 µg combined with various progestins like levonorgestrel, desogestrel, drospirenone, gestodene, or cyproterone acetate.
Specific Formulations with 30-35 µg Ethinyl Estradiol
The following represent commonly available higher-dose COC formulations:
30 µg Ethinyl Estradiol Combinations:
- Levonorgestrel 150 µg + EE 30 µg (21/7 regimen) - This serves as the reference standard in VTE risk assessment 1
- Desogestrel 150 µg + EE 30 µg (Marvelon/Desolett) - Demonstrated excellent cycle control with low side effect incidence 2
- Drospirenone 3 mg + EE 30 µg (21/7 regimen) - Shows higher scheduled withdrawal bleeding rates compared to lower-dose alternatives 3
- Gestodene + EE 30-40 µg - Associated with lower VTE risk among higher-dose formulations 1
- Cyproterone acetate + EE 30-40 µg - Also demonstrates relatively lower VTE risk in this category 1
35 µg Ethinyl Estradiol Combinations:
Pills containing 35 µg EE are also available with various progestins, though specific brand names vary by region.
Important Clinical Considerations
The trend in contraceptive prescribing has shifted toward lower estrogen doses (20 µg) due to safety concerns, particularly regarding venous thromboembolism risk. Research demonstrates that all COCs with 30-40 µg ethinyl estradiol show significantly increased VTE risk compared to non-users, with the magnitude varying by progestin type 1.
VTE Risk Hierarchy (30-40 µg EE formulations):
From the 2018 meta-analysis 1:
- Highest risk: Desogestrel combinations (RR: 1.46,95% CI: 1.33-1.59)
- Intermediate risk: Drospirenone combinations
- Lowest risk: Gestodene (RR: 1.27) and cyproterone acetate (RR: 1.29) combinations
Trade-offs with Higher Estrogen Content:
Benefits of 30 µg formulations:
- Superior cycle control with less breakthrough bleeding 4
- Higher rates of scheduled withdrawal bleeding (95-100% vs 82-92% with 20 µg) 3
- Lower discontinuation rates due to bleeding irregularities 4
Drawbacks:
- Increased VTE risk across all formulations 1
- Greater impact on hemostatic parameters 5
- Higher rates of estrogen-related side effects
Clinical Pitfall to Avoid
Do not prescribe higher-dose (30-35 µg) COCs as first-line therapy in 2024. The evidence strongly supports using the lowest effective estrogen dose. Historical data showing non-contraceptive benefits (decreased dysmenorrhea, functional ovarian cysts, etc.) largely comes from studies using formulations with >35 µg EE or 50 µg mestranol 6, which are no longer recommended due to safety concerns.
Reserve 30 µg formulations for women who experience unacceptable breakthrough bleeding on 20 µg preparations and have no contraindications to higher estrogen exposure 4. Even then, consider newer alternatives like estradiol valerate or estetrol-based formulations, which demonstrate lower impact on coagulation parameters while maintaining efficacy 5, 7.